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EFFECT OF 1 % AND 2% PROPOFOL
ON BLOOD LIPIDS DURING LONG-
TERM SEDATION
Andre Coetzee, Edward M Blaine, D Labadarios,
Robert Schall, Matthias Haus
Objectives. To compare the effects of 1% and 2% propofol on
the maximum and average lipid levels, the relative frequency
of hyperlipidaemia, the propofol dose required to achieve an
equivalent degree of sedation, the pharmacodynamic effects
at the required infusion rates, and the effect on respiratory
function.
Design. Open, randomised, parallel group, multicentre
comparison study.
Setting. Intensive care units (lCUs) at the Faculty of Medicine,
University of Stellenbosch and at Vergelegen Medicity,
Somerset West.
Subjects. Patients who were artificially ventilated for at least
72 hours in the rcus and who required sedation or analgesia.
Outcome measures. Continuous intravenous infusion of 1% or
2% propofol to provide an administration rate in the range of
1 - 4 mg/kg/h. The initial infusion rate was about 2
mg/kg/h, adjusted to achieve the appropriate levelpf
sedation.
Results and conclusions. Seventy-five patients were enrolled in
the study, of which 72 were evaluable for safety analysis and
58 were evaluable for efficacy analysis. The total daily dose
of propofol (ml/day) in the 2% propofol group was about
60% of that in the 1% propofol group, indicating that the
lipid load in the 2% propofol group had only slightly more
than half the lipid load in the 1% propofol group. Thirteen of
27 patients (48%) in the 2% propofol group had abnormally
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high triglyceride levels compared with 19 of 31 patients (61 %)
in the 1% propofol group. Similarly, 1 of 22 patients (4%) in
the 2%. propofol group had lipaemia compared with 4 of 30
patients (13%) in the 1% propofol group. Abnormal
cholesterol levels, alveolar-arterial oxygen tension gradient
and daily percentage of time with desired sedation were
comparable between the two groups. The observed incidence
of raised plasma triglyceride concentrations, and of lipaemia,
was lower in the 2% propofol group than in the 1% propofol
group, although the differences were not statistically
significant. The 2% formulation of propofol appears to be as
effective and at least as safe as 1% propofol.
5 Afr Med J 2002; 92: 911-916.
The 1% formulation of propofol (Diprivan, AstraZeneca) is
used widely for induction and maintenance of anaesthes{a and
in some countries for sedation of adult patients receiving
intensive care. To reduce the amount of lipid administered in
association with propofol, a 2% formulation of propofol has
been developed. This formulation contains 20 mg/m! propofol
and an unchanged amount of soybean oil 00%). Therefore for
any given dose of propofol the lipid load is reduced by 50%
when compared with the 1% solution.
In four clinical studies which compared the 2% propofol
formulation with the standard 1% formulation, pharmaco-
dynamic equivalence and similar pharmacokinetic parameters
were demonstrated and no significant differences in the safety
profiles of the two preparations were encountered l -4 In one of
the studies; however, a significantly greater increase in plasma
triglyceride concentration was observed in patients given 1%
propofol. In another study' in which plasma triglyceride
concentration was measured, no difference was observed. This
may have been due to the relatively low total lipid load·
administered in this study.
Some publications•. 7 have suggested that the prolonged
infusion of 1% propofol may be associated with increased dose
requirements to maintain the desired level of sedation in
intensive care. In some cases this has been associated with
hypertriglyceridaemia.
Greene et al.s investigated the effect of Intralipid-induced
hyperlipidaemia on pulmonary function and concluded that
the minor changes observed were unlikely to be of any clinical
consequence in patients v.'ithout any pre-existing pulmonary or
pulmonary vascular disease. While no consistent effect on
pulmonary function was observed in the studies that included
2% propofol, there was a trend at some time points suggesting
a reduction in alveolar-arterial oxygen gradient.
The principal objectives of this study, therefore, were to
compare 1% and 2% propofol with regard to maximum and
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average lipid (triglyceride and cholesterol) levels and the
relative frequency of hyperlipidaemia (i.e. an increase in serum
triglyceride level above the upper limit of the normal range),
the propofol dose required to achieve an equivalent degree of
sedation, and the effect on respiratory function, and in
particular arterial oxygenation.
METHODS
Study population
Patients of either sex, at least 18 years old, who were artificially
ventilated for at least 72 hours in the ICUs and who required
sedation or analgesia, were enrolled in this study. Exclusio~
criteria included allergy to the trial drugs, previous adverse
experience of general anaesthesia or sedation, pregnancy, head
injury or coma, use of neuromuscular blocking drugs other
than short-acting agents required to facilitate the insertion of
an endotracheal tube, disorders of lipid metabolism, and the
use of intravenous lipids other than propofol.
Informed consent was given by the patient or next of kin.
Approval from the relevant ethics committees was obtained for
the study.
Study design
This was an open, randomised, parallel group, multicentre
(two-centre) comparison of 1% and 2% propofol. The intended
duration of therapy with propofol was at least 72 hours. When
necessary, patients in both groups were treated with an
infusion of morphine 1 - 2 mg/h, started at the same time as
the infusion of propofol. The study treatments were: (i) 1%
propofol2 mg/kg/h; and (ii) 2% propofol2 mg/kg/h.
Patients were sedated v.-ith a continuous intravenous
infusion of 1% or 2% propofol to provide an administration
rate in the range of 1 - 4 mg/kg/h. The initial infusion rate
was about 2 mg/kg/h; thereafter it was adjusted to achieve the
appropriate level of sedation. Wherever possible, sedation was
initiated v.-ith an infusion of propofol. All patients were
ventilated v.-ith oxygen-enriched air to maintain arterial carbon
dioxide tension (PaC02) at 4.0 - 5.5 kPa. The infusion of
propofol was discontinued when the patient was to be weaned
from the ventilator.
Concomitant medication such as antibiotics, inotropic agents
and intravenous fluids were given to the patients as required.
Lipid emulsion-free total parenteral nutrition was administered
to these patients who met the criteria for nutrition support.
Efficacy assessment
For each study day, the total volume of propofol used was
recorded. The total duration and daily dose of propofol were
recorded, and the daily infusion rate (mg/kg/h) was calculated
in the analysis. The dose of morphine used (mg) was
calculated in the same way. The level of sedation was assessed
daily using a modification of the scale proposed by Ramsay et
ai'
A baseline venous blood sample was collected before the
initiation of the propofol sedation, for measurement of plasma
triglyceride and cholesterol concentration. Thereafter, venous
blood samples were taken at the same time each day during
the period of propofol administration and 24 hours following
the last dose of propofol. The presence of any lipaemia on
visual inspection of plasma samples was noted.
Statistical analysis
The two treatInent groups were compared with regard to the
following variables:
1. Primary criteria: (i) maximum and average lipid concen-
tration for the time period on propofol treatment (infusion);
(ii) relative frequency of hypertriglyceridaemia (occurrence of
abnormal lipid levels, presence of lipaemia ascertained by
visual inspection) - the normal range for triglyceride was
0.9 mmo1/1- 1:97 mmo1/1 and for cholesterol 3.8 mmo1/1 - 5.7
mmo1/1; (iii) propofol dose rates; and (iv) alveolar-arterial
oxygen tension gradient for each day during propofol infusion.
2. Secondary criteria: (i) percentage of time with adequate
sedation; and (ii) overall assessment of sedation.
The two treatment groups were compared with regard to
maximum and average plasma lipid concentration (triglyceride
and cholesterol), dose rates, and the alveolar-arterial oxygen
tension gradient by calculating estimates and 95% confidence
intervals (CIs) for the true 2% propofol/1 % propofol mean
ratios in these variables. Estimates and Cls for the mean ratios
were calculated by taking the antilog of the conventional point
estimates and confidence limits for mean differences obtained
from an analysis of variance (ANOVA) of the log-transformed
data with treatment and centre as main effects. The two
treatment groups were also compared with respect to the
proportion of patients with abnormal lipid levels, and with
regard to the proportion of patients with lipaemia, by
calculating estimates and 95% CIs for the true 2% propofol-
1% propofol difference in those proportions between the
treatment groupS.lO
RESULTS
Data sets analysed
Seventy-five patients were enrolled in the study, of which 72
received treatment. All patients who received treatment were
evaluable for safety analysis and 58 patients were evaluable for
efficacy analysis. Seventeen patients were excluded from the
efficacy analysis for the following reasons: violation of entry
criteria (N = 1), did not receive propofol (N = 3), protocol
violations (N = 2), less than 72 hours of propofol treatment
Table I. Demographic data (efficacy population)
1% propofol 2% propofol
(N=31) (N= 27)
Male Female Male Female
No. of patients 14 17 18 9
Age (yrs)
Mean 48.5 43.8 50.3 44.3
Range 21.6 - 71.0 19.9 - 76.1 22.6 - 71.0 19.5 - 76.4
Weight (kg)
Mean 75.1 66.6 73.8 62.3
Range 58.2 - 110 55.0 - 90.0 55.0 - 92.0 50.0 - 90.0
Apache II score
Median 14 11 14.5 9.5
Range 3 - 22 3 - 27 3 - 26 2 - 22
(N =8), and raised triglyceride levels before propofol infusion
(N =3). The demographic data of the patients evaluable for
efficacy analysis are summarised in Table 1.
Adverse events
Raised triglyceride levels were the most frequently reported
adverse event, occurring in 10 out of 37 patients (27%) in the
1% propofol group and 4 out of 35 patients (11 %) in the 2%
propofol group.
Deaths
One patient died as a result of trauma "before starting treatment
with propofol. Six patients died after start of the propofol
infusion: 2 patients had cardiac arrest (l patient in each group,
definitely not related to propofol); 1 patient had pulmonary
oedema with underlying tuberculosis (2% propofol group,
probably not related to propofol); 1 patient was
hyperglycaemic on admission (2% propofol group, definitely
not related to propofol); 1 patient died after a hypertensive
episode with ventricular arrhythmias and asystole (2%
propofol group, probably not related to propofol); 1 patient
died from multiple organ failure (l % propofol group, probably
not related to propofoD.
Lipid levels
Fewer patients in the 2% propofol group had abnormally
raised plasma triglyceride concentrations compared with the
1% propofol group. Abnormal cholesterol levels occurred with
similar frequency in the two groups, but fewer patients in the
2% propofol group had lipaemia than in the 1% propofol group
(Table ID.
The observed maximum and average concentrations of
plasma triglyceride and cholesterol were lower in the 2%
propofol group compared with the 1% propofol group,
Propofol and morphine infusion times and doses
Alveolar-arterial oxygen tension gradient
Table n. Number and proportion of patients with abnormal
plasma lipid levels*(efficacy population)
The two treatments were similar with regard to the alveolar-
arterial oxygen tension gradient (Table N).
although the corresponding Cl for the 2% propofol/1 %
propofol mean ratios were wide and included 100%, so that a
statistically significant difference could not be shown (Table III).
125 119
(28 - 262) (68 - 231)
1775 1039
(350 - 3 946) (205 - 1 910)
360' 219
(I21 - 838) (70.3 - 509)
86.2 81.3
(0 - 268) (0 - 174)
221 153
(0 - 1 157) (0 - 368)
92.9 91.9
(40 - 100) (66 - 100)
1% propofol 2% propofol
(N =31) (N =27)
Daily dose of propofol (ml/day)
Table V. Mean values (ranges) of propofol and morphine infusion
time and doses (efficacy population)
Average % desired sedation
Total duration of propofol (h)
Total dose of propofol (ml)
Total duration of morphine (h)
Total dose of morphine (mg)
The mean values and ranges of the dose rates of propofol and
morphine are summarised in Table V. The average daily dose
of propofol (ml/day) in the 2% propofol group was about 60%
of that in the 1% propofol group, indicating that the 2%
propofol group had only slightly more than half the lipid load
Differencet 95% Cr
2%
propofol
1%
propofol
Abnormal
triglyceride(%) 19/31 (61) 13/27 (48) -13 -39 -12
Abnormal
cholesterol§ 3/31 (IO) 3/27 (I2) 1 -14 -17
Lipaemia (%) 4/30 (I3) 1/27 (4) -9 -23-5
.. Triglyceride levels above normal range, cholesterol levels below normal range
or visible lipaemia. any time during propofol treatment normal range for
triglyceride was 0.9 mmol/l - 1.97 mmol/l and for cholesterol 3.8 mmol/l - 5.7
mmol/l.
t 2% propofol- 1% propofol difference of proportions.
t 95% confidence interval (Cl) for the 2% propofol - 1% propofol difference of
proportions.
§ All abnormal cholesterol levels were below normal
Table m. Maximum and average concentration (mmolll) of plasma triglycerides and cholesterol (efficacy population)
1% propofol 2% propofol
Geometric Geometric Mean ratio
N mean SD Range N mean SD Range (%)t 95% Cl (%)t
Triglycerides
Cmax 31 2.32 1.58 0.80 - 5.47 27 2.02 1.61 0.84 - 6.52 87 68 -111
Cav 31 1.58 1.47 0.63 -3.22 27 1.37 1.56 0.59 - 3.91 87 70 -108
Cholesterol
Cmax 31 3.72 1.39 2.13 - 6.10 27 3.25 1.51 1.14 - 6.44 87 72 -106
Car 31 2.85 1.44 1.34 - 4.99 27 2.48 1.48 0.88 - 5.35 87 71-106
>I- Point estimate for 2% propofol/l % propofol mean ratio hom analysis of variance \\'ith treatment and centre as main effects.
t 95% confidence interval (CD for the 2% propofol/l % propofol mean ratio from analysis of variance with treatment and centre as main effects.
SD = standard deviation; Cmax = maximum concentration; Cav = average concentration.
Table Iv. Alveolar-arterial oxygen tension gradient (efficacy population)
1% propofol 2% propofol
Geometric Geometric Mean. ratio 95% Cl
N mean SD Range N mean SD Range (%)* (%)t
D Day 1 30 266 1.57 130 - 637 26 223 1.46 81.0 - 611 84 67 -105
Day 2 30 223 1.43 136 - 667 26 230 1.31 151 - 429 103 87 -103
Day 3 27 221 1.49 112 -570 26 225 1.37 109 - 400 102 84-124
Day 4 28 218 1.52 104 - 604 26 220 1.46 92.1 - 464 101 81-126
Day 5 26 205 1.44 120 - 551 21 226 1.46 107 - 568 110 88 -136
* Point estimate for 2% propofol/l % propofol mean ratio from an~ysis of variance \'\rith treatment and centre as main effects.
t 95% confidence interval (Cl) for the 2% propofol/l% propofol mean ratio from analysis of variance ,,~th treatment and centre as main effects.
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DISCUSSION
Sedation
Table VI. Overall quality and control of sedation (efficacy
population)
levels in non-septic patients during the 1% propofol
administration. Eddleston and Shelley,19 however, reported a
significant increase in triglyceride and cholesterol levels in a
single patient who received prolonged propofol sedation. The
2% propofol solution was used for intensive care sedation and
this did not result in demonstrative pulmonary dysfunction in
either the 1% or 2% propofol group.'"
The concern about the effect of raised serum triglycerides on
pulmonary function was extrapolated from the fat embolism
syndrome and it was speculated that lipids given
intravenously impair lung function and gas exchange."
However, clinical studies have revealed a less clear picture:
following a 0.24 g/kg/h dose (for 16 hours) of intravenous
lipids, Van Deyk et al.22 could not demonstrate any change in
pulmonary artery pressure and the shunt fraction in patients
suffering from acute respiratory distress syndrome (ARDS) and
sepsis who received intravenous lipids.23 In addition, the
pulmonary artery wedge pressure increased while the systemic
vascular resistance decreased after the administration of
lipids.23
The mechanism for the alteration in pulmonary function and
pulmonary haemodynamics is not clear. Early studies
suggested impaired diffusion associated with a raised serum
triglyceride level.23 More recent data indicate that altered
prostaglandin production could explain the observed changes
in pulmonary function. McKeen et al." demonstrated a
decreased arterial oxygen tension and increased pulmonary
artery pressure during 10% Intralipid infusion (0.25 g/kg/h),
which could be blocked with indometacin (but not heparin)
administration. It has been speculated that intravenous lipids
increase the vasodilatory prostanoids resulting in ventilation-
perfusion mismatch in the lung.'4-26 However, no cause-and-
effect relationship (for lipids, prostaglandins and altered
pulmonary function) has been demonstrated in human
studies.v The effect of lipids on pulmonary function is small
and is unlikely to have clinical consequences."·"
In our study we used the AaD02 to evaluate pulmonary
function. However, one needs to interpret the AaD02 carefully
as it has been demonstrated that this index is influenced by the
inspired oxygen fraction.29 In addition, poor correlation was
found between the Qs/Qt and AaD02 and it was speculated
that the mixed venous oxygen saturation has a significant effect
on the AaD02.29 However, despite this criticism, it can be stated
that in this study the infusion of either 1% or 2% propofol did
not appear to have any influence on the clinician's ability to
oxygenate the patients.
Hypertriglyceridaemia has been reported to predispose to
pancreatitis.30• 31 Triglyceride levels in excess of 11.3 mmol/l
increase the likelihood of pancreatitis and although there is an
association between alcohol ingestion, triglycerides and
pancreatitis, it does appear that raised triglycerides per se can
cause pancreatitis.30
7 -15 -29
3 -21-27
Difference* 95%
(%) Cl (%)b
2%
propofol
1%
propofol
Quality
Good (%) -, 22/30 21/26.
(73) (81)
Adequate (%) 8/30 4/26
(27) (15)
Poor (%) 0/30 1/26
(0) (4)
Control
Good (%) 21/30 19/26
(70) (73)
Adequate (%) 9/30 7/26
(30) (27)
Poor (%) 0/30 0/26
(0) (0)
The treatment groups are similar with regard to the daily
percentage of time with desired sedation (Table V). Twenty-
two of 30 patients (73%) in the 1% propofol group and 21 of 26
patients (81 %) in the 2% propofol group had a good quality of
sedation. Similarly, 21 of 30 patients (70%) in the 1% propofol
group and 19 of 26 patients (73%) in the 2% propofol group
had good control of sedation (Table VI).
of the 1% propofol group. The total dose of morphine in the
2% propofol group is about 30% lower than in the 1% propofol
group.
• 2% propofol - 1% propofol difference of proportions.
t 95% confidence interval (CD for the 2% propofol- 1% propofol difference of
proportions.
Propofol has a suitable pharmacokinetic profile for use in the
ICD and a number of studies have indeed confirmed that
propofol offers good quality sedation, is easily adjustable and
has a short wake-up time when used as an intravenous agent
in intensive care.n-17 Our results support those published
previously inasmuch as we found propofol easy to use and
with few or no serious side-effects. In addition, we could not
demonstrate any difference in either the management of the
infusion regimen, or in the incidence of side-effects when we
compared the 1% with the 2% propofol solution.
There has been concern about the effects of intravenous
lipids on pulmonary and pancreatic function. A number of
studies evaluated the effect of 1% and 2% propofol on serum
triglycerides, cholesterol and pulmonary function. Gottardis
and colleagues" could not show any change in serum lipid
1.
2.
J.
4.
5.
6.
m 7.
8.
9.
10.
Because of the potential detrimental effect of raised serum
triglycerides on patients, we screened patients for raised
triglycerides before commencing the propofol infusion. This
may have introduced bias inasmuch as we excluded a group
that was at risk for developing further raised lipid levels.
However, it was not thought to be acceptable ethically to
subject patients, who already have raised triglycerides, to a
further risk and hence this exclusion criterion was deemed
necessary.
In this study the total daily dose of propofol (ml/day) in the
2% propofol group was about 60% of that in the 1% propofol
group, indicating that the lipid load in the 2% propofol group
was slightly higher than half the lipid load in the 1% propofol
group. The observed incidence of raised triglyceride levels and
of lipaemia was lower in the 2% propofol group than in the 1%
propofol group. However, because of the relatively small
sample size no definite conclusion in favour of the 2% propofol
treatment can be made. It does, however, appear that the 2%
propofol solution is as safe as the 1% solution in this respect.
Furthermore, it does not seem that propofol, as used in this
trial, interferes with pulmonary function of critically ill patients
and whatever changes there may have been were comparable
beh-veen the two groups. Nevertheless, the use of the more
concentrated 2% propofol solution would imply that a smaller
load of lipid emulsion would have to be administered to the
patient. This may hold distinct advantages for the patient in
view of the recently reported increased susceptibility to
infection and decreased T-cell function in trauma patients
receiving lipid infusions (25% of non-protein energy) as part of
total parenteral nutrition.32
We conclude that the results of this comparative trial indicate
that the efficacy and safety of the two treatments are similar.
This study was financially supported by AstraZeneca
Pharmaceuticals.
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